Genentech, Inc.

Xenon Pharmaceuticals Inc.

Gilead Connecticut, Inc.

Genetech, Inc.

Constellation Pharmaceuticals, Inc.

F. Hoffmann-la Roche Ag

Hoffmann-la Roche Inc.

Daniel Fred Ortwine

Wendy B Young

Xiaojing Wang

Jun Liang

James John Crawford

BinQing Wei

Sharada Shenvi Labadie

Birong Zhang

Daniel P Sutherlin

Christoph Martin Dehnhardt

Shaoyi Sun

Brian Salvatore Safina

Sultan Chowdhury

Nicholas Charles Ray

Qi Jia

Alla Yurevna Zenova

Ivan William Hemeon

Kevin S Currie

Scott A Mitchell

Peter A Blomgren

Jeffrey E Kropf

Jianjun Xu

Seung H Lee

Zhongdong Zhao

Thilo Focken

Aaron C Schmitt

Michael Edward Grimwood

Tao Wang

Nicholas D Smith

Jean-Christophe P Harmange

Peter Scott Dragovich

Mehmet Kahraman

Steven P Govek

Victor S Gehling

Johnny Yasuo Nagasawa

Joseph P Lyssikatos

Brian K Albrecht

Anthony A Estrada

Zhonghua Pei

Frederick Cohen

Steven F Bellon

Richard Pastor

Richard A Goldsmith

Jun M Li

Simon Charles Goodacre

Jason R Zbieg

Pavel E Zhichkin

Antonio J M Barbosa

Zhiguo Liu

Honglu Zhang

Ravi Krishnamoorthy

Michael Scott Wilson

Jean-Christophe Andrez

Kwong Wah Lai

Andiliy Gokching Lai

Binqing Wei

Jiuxiang Zhu

Shannon Marie Decker

Tao Sheng

Andrew D White

Paul Robert Bichler

Jiangpeng Liao

Antonio J Barbosa

Chien-An Chen

Michael F T Koehler

Cuong Q Ly

Philippe Bergeron

James Richard Kiefer, Jr

John Wai

Abid Hasan

Wei Gong

William Martin Rennells

Jun Li

Kevin Hon Luen Lau

Tommy Lai

Xianrui Zhao

James Kiefer

Maia Vinogradova

Jason Zbieg

John Sui-Man Wai

Jason Burch

William M Rennells

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure:  and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Heteroaryl pyridone and aza-pyridone compounds

Described herein are heteroaryl compounds with estrogen receptor modulation activity or function having the Formula I, II, and III structures: and

Heteroaryl estrogen receptor modulators and uses thereof

Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: 

Tetrahydronaphthalene estrogen receptor modulators and uses thereof

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyridone and aza-pyridone compounds and methods of use

The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.

Substituted benzamides and methods of use thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Heterocyclic estrogen receptor modulators and uses thereof

Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Heteroaryl pyridone and aza-pyrodine compounds

Provided are compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using the present composition in the treatment of various disorders.

Pyrazolo compounds and uses thereof

The present invention relates to compounds useful as inhibitors of one or more histone demethylases, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.

Pyrrolidine amide compounds as histone demethylase inhibitors

Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Described herein are tetrahydroisoquinoline compounds with estrogen receptor modulation activity or function having the Formula I structure: 

Tetrahydroisoquinoline estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators of Formula (I): 

Estrogen receptor modulators and uses thereof

Growing community of inventors

San Ramon, CA, United States of America

Daniel Fred Ortwine